Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Up 17,702.6% in May

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the recipient of a significant increase in short interest during the month of May. As of May 29th, there was short interest totaling 68,896 shares, an increase of 17,702.6% from the May 14th total of 387 shares. Based on an average daily volume of 778,450 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.1% of the shares of the company are short sold.

Matinas Biopharma Stock Performance

Matinas Biopharma stock traded down $0.02 during midday trading on Tuesday, hitting $0.80. 102,880 shares of the company were exchanged, compared to its average volume of 96,069. The firm has a market capitalization of $5.11 million, a PE ratio of -0.40 and a beta of 1.67. Matinas Biopharma has a fifty-two week low of $0.48 and a fifty-two week high of $3.09. The business has a fifty day simple moving average of $0.62 and a two-hundred day simple moving average of $0.65.

Matinas Biopharma (NYSEAMERICAN:MTNB) last posted its earnings results on Friday, May 8th. The company reported ($0.30) EPS for the quarter.

Institutional Trading of Matinas Biopharma

A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC purchased a new position in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned about 0.72% of Matinas Biopharma at the end of the most recent reporting period. Institutional investors and hedge funds own 11.77% of the company’s stock.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.